Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension, Marking Market Entry

Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension, Marking Market Entry​

Mumbai, Beijing, May 22, 2026: Global pharmaceutical major Lupin Limited today announced that China's National Medical Products Administration has approved its Abbreviated New Drug Application for Oseltamivir Phosphate. This development was achieved in partnership with Yabao Pharmaceuticals, a recognized leader in China's pediatric medicine market. The approval represents Lupin's first product entry into the Chinese market, marking a significant milestone in its global expansion strategy.

The approved product, Oseltamivir Phosphate for oral suspension, 6 mg/mL, is slated for launch and commercialization. The product is intended to expand access to high-quality, affordable medicines, particularly for pediatric use.

The indications for Oseltamivir Phosphate for oral suspension, 6 mg (base)/mL are as follows:


Fabrice Egros, President - Corporate Development, Lupin, stated, "We are delighted that we have received approval for Oseltamivir Oral Suspension in China. This is a strategic step in our entry into one of the world's largest pharmaceutical markets. It reflects our shared commitment to expanding access to high-quality, affordable therapies, particularly in pediatric care. We look forward to building a stronger presence in this market through our partnership."

Wei Ren, President, Yabao, added, "We are pleased to announce the official approval of Oseltamivir Oral Suspension in China, marking a key milestone in our partnership with Lupin. It reinforces Yabao's dedication to quality pediatric medicines and showcases our strong collaboration. We will further expand our R&D portfolio for pediatric and adult chronic disease drugs to jointly advance our businesses."

***

Company Profiles​

Lupin Limited
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India. The company's products are distributed in over 100 markets, specializing in pharmaceutical products such as branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin is trusted by healthcare professionals and consumers globally, maintaining a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. The company operates 15 state-of-the-art manufacturing sites and 7 research centers globally, supported by a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries: Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Yabao Pharmaceutical Co.
Yabao Pharmaceutical Co. (Shanghai Stock Exchange 600351) is a leading Chinese pharmaceutical company with fully integrated development, manufacturing, and commercialization capabilities within China. While maintaining its established business in modern traditional Chinese medicines and chemical generics, Yabao is pursuing strategic development of innovative pharmaceuticals. Beyond strong clinical and regulatory capabilities, the company has solid expertise in formulation and API production and meets good manufacturing practice (cGMP) requirements with two manufacturing sites approved by the U.S. FDA and a European agency.

LUPIN Stock Price Movement​

Shares of Lupin Limited today shed 0.60% to settle at ₹2281.8, dropping ₹13.80 in after-hours trading. The stock traded on a total volume of 1.23 million shares, remaining within its ₹2270 to ₹2304.5 intraday range.